Anti-Gal-mediated targeting of human B lymphoma cells to antigen-presenting cells: A potential method for immunotherapy using autologous tumor cells

Haematologica

Volumn 90, Issue 5, 2005, Pages 625-634

  Manches, Olivier ^b   Plumas, Joel ^a   Lui, Gabrielle ^b   Chaperot, Laurence ^b   Molens, Jean Paul ^b   Sotto, Jean Jacques ^b   Bensa, Jean Claude ^b   Galili, Uri ^b  

^a ETABLISSEMENT FRANÇAIS DU SANG   (France)

^b NONE

Author keywords

Anti Gal; Anti gal epitope; APC targeting; Lymphoma vaccine; Phagocytosis

Indexed keywords

ALPHA 1,3 GALACTOSYLTRANSFERASE; CANCER VACCINE; CD1 ANTIGEN; CD14 ANTIGEN; CD16 ANTIGEN; CD19 ANTIGEN; CD1C ANTIGEN; CD3 ANTIGEN; CD32 ANTIGEN; CD56 ANTIGEN; CD64 ANTIGEN; CD86 ANTIGEN; EPITOPE; FC RECEPTOR; GALACTOSE ANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA DR3 ANTIGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 13; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; N ACETYLLACTOSAMINE SYNTHASE; SIALIDASE; TUMOR ANTIGEN; TUMOR VACCINE; UNCLASSIFIED DRUG; URIDINE DIPHOSPHATE GALACTOSE;

ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; B CELL LYMPHOMA; CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; GLYCOSYLATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOTHERAPY; MACROPHAGE ACTIVATION; MAJOR HISTOCOMPATIBILITY COMPLEX; OPSONIZATION; PHAGOCYTOSIS; TARGET CELL; TUMOR CELL CULTURE;

AMINO SUGARS; ANIMALS; ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; CALLITHRIX; CANCER VACCINES; CELLS, CULTURED; GALACTOSYLTRANSFERASES; GLYCOSYLATION; HUMANS; IMMUNITY, NATURAL; IMMUNIZATION; IMMUNOGLOBULIN G; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; LYMPHOMA, B-CELL; NEURAMINIDASE; PHAGOCYTOSIS; RECEPTORS, IGG; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTE SUBSETS; TRISACCHARIDES; TUMOR STEM CELLS;

EID: 20344396137     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Chaperot L, Delfau-Larue MH, Jacob MC, Molens JP, Roussel B, Agrawal S, et al. Differentiation of antitumor-specific cytotoxic T lymphocytes from autologous tumor infiltrating lymphocytes in non-Hodgkin's lymphoma. Exp Hemtaol 1999;27:1185-93.
2. Maass G, Schmidt W, Berger M, Schilcher F, Koszik F, Schneeberger A, et al. Priming of tumor-specific T cells in the draining lymph nodes after immunization with interleukin 2-secreting tumor cells: three consecutive stages may be required for successful tumor vaccination. Proc Natl Acad Sci USA 1995;92:5540-4.
3. Zinkernagel RM, Ehl S, Aichele P, Oehen S, Kundig T, Hengartner H. Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity. Immunol Rev 1997;156:199-209.
4. Ochsenbein AF, Klenerman P, Karrer U, Ludewig B, Pericin M, Hengartner H, et al. Immune surveillance against a solid tumor fails because of immunological ignorance. Proc Natl Acad Sci USA 1999;96:2233-8.
5. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991-8.
6. Unkeless JC. Function and heterogeneity of human Fc receptors for immunoglobulin G. J Clin Invest 1989;83:355-61.
7. Schmitt DA, Hanau D, Bieber T, Dezutter-Dambuyant C, Schmitt D, Fabre M, et al. Human epidermal Langerhans cells express only the 40-kilodalton Fcγ receptor (FcRII). J Immunol 1990;144:4284-90.
8. Fanger NA, Wardwell K, Shen L, Tedder TF, Guyre PM. Type I (CD64) and type II (CD32) Fc gamma receptor-mediated phagocytosis by human blood dendritic cells. J Immunol 1996; 157:541-8.
9. Ravetch JV, Clynes RA. Divergent roles for Fc receptors and complement in vivo. Annu Rev Immunol 1998; 16: 421-32.
10. Regnault A, Lankar D, Lacabanne V, Rodriguez A, Thery C, Rescigno M, et al. Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med 1999;189:371-80.
11. Albert ML, Pearce SF, Francisco LM, Sauter B, Roy P, Silverstein RL, et al. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med 1998;188:1359-68.
12. Nair S, Buiting AM, Rouse RJ, Van Rooijen N, Huang L, Rouse BT. Role of macrophages and dendritic cells in primary cytotoxic T lymphocyte responses. Int Immunol 1995;7:679-88.
13. Machy P, Serre K, Leserman L. Class I-restricted presentation of exogenous antigen acquired by Fcgamma receptor-mediated endocytosis is regulated in dendritic cells. Eur J Immunol 2000; 30:848-57.
14. Villinger F, Mayne AE, Bostik P, Mori K, Jensen PE, Anmed R, et al. Evidence for antibody-mediated enhancement of simian immunodeficiency virus (SIV) Gag antigen processing and cross presentation in SIV-infected rhesus macaques. J Virol 2003;77:10-24.
15. Stager S, Alexander J, Kirby AC, Botto M, Rooijen NV, Smith DF, et al. Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8+ T-cell responses. Nat Med 2003;9:1287-92.
16. Dyall R, Vasovic LV, Clynes RA, Nikolic-Zugic J. Cellular requirements for the monoclonal antibody-mediated eradication of an established solid tumor. Eur J Immunol 1999;29:30-7.
17. Galili U, Rachmilewitz EA, Peleg A, Flechner I. A unique natural human IgG antibody with anti-α-galactosyl specificity. J Exp Med 1984;160:1519-31.
18. Galili U, Macher BA, Buehler J, Shohet SB. Human natural anti-alpha-galactosyl IgG. II. The specific recognition of α (1-3)-linked galactose residues. J Exp Med 1985;162:573-82.
19. Galili U. Interaction of the natural anti-Gal antibody with alpha-galactosyl epitopes: a major obstacle tor xenotransplantation in humans. Immunol Today 1993;14:480-2.
20. Galili U, Mandrell RE, Hamahdeh RM, Shohet SB, Griffis JM. Interaction between human natural anti-α-galactosyl immunoglobulin G and bacteria of the human flora. Infect Immun 1988;56:1730-7.
21. Galili U, Clark MR, Shohet SB, Buehler J, Macher BA. Evolutionary relationship between the natural anti-Gal antibody and the Gal α1α3Gal epitope in primates. Proc Natl Acad Sci USA 1987;84:1369-73.
22. Galili U, Shohet SB, Kobrin E, Stults CLM, Macher BA. Man, apes, and Old World monkeys differ from other mammals in the expression of α-galactosyl epitopes on nucleated cells. J Biol Chem 1988;263:17755-62.
23. Collins BH, Cotterell AH, McCurry KR, Alvarado CG, Magee JC, Parker W, et al. Cardiac xenografts between primate species provide evidence for the importance of the α-galactosyl determinant in hyperacute rejection. J Immunol 1995;154:5500-10.
24. Unfer RC, Hellrung D, Link CJ Jr. Immunity to the α(1,3)galactosyl epitope provides protection in mice challenged with colon cancer cells expressing α(1,3)galactosyl-transferase: a novel suicide gene for cancer gene therapy. Cancer Res 2003;63:987-93.
25. LaTemple DC, Henion TR, Anaraki F, Galili U. Synthesis of α-galactosyl epitopes by recombinant α1,3 galactosyl-transferase for opsonization of human tumor cell vaccines by anti-galactose. Cancer Res 1996;56:3069-74.
26. Galili U, LaTemple DC. Natural anti-Gal antibody as a universal augmenter of autologous tumor vaccine immunogenicity. Immunol Today 1997;18:281-5.
27. Plumas J, Chaperot L, Jacob MC, Molens JP, Giroux C, Sotto JJ, et al. Malignant B lymphocytes from non-Hodgkin's lymphoma induce allogeneic proliferative and cytotoxic T cell responses in primary mixed lymphocyte cultures: an important role or costimulatory molecules CD80 (B7-1) and CD86 (B7-2) in stimulation by tumor cells. Eur J Immunol 1995;25: 3332-41.
28. Chaperot L, Chokri M, Jacob MC, Drillat P, Garban F, Egelhofer H, et al. Differentiation of antigen-presenting cells (dendritic cells and macrophages) for therapeutic application in patients with lymphoma. Leukemia 2000;14: 1667-77.
29. LaTemple DC, Abrams JT, Zhang SY, Galili U. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for α1,3galactosyltransferase. Cancer Res 1999;59:3417-23.
30. Galili U, Buehler J, Shohet SB, Macher BA. The human natural anti-Gal IgG. III. The subtlety of immune tolerance in man as demonstrated by crossreactivity between natural anti-Gal and anti-B antibodies. J Exp Med 1987; 165:693-704.
31. Henion TR, Macher BA, Anaraki F, Galili U. Defining the minimal size of catalycally active primate α1,3galactosyl-transferase: structure function studies on the recombinant truncated enzyme. Glycobiology 1994;4:193-201.
32. Chen ZC, Tanemura M, Galili U. Synthesis of α-gal epitopes (Galα1-SGalβ1-4GlcNAc-R) on human tumor cells by recombinant α1,3galactosyl-transferase produced in Pichia pastoris. Glycobiology 2001;11:577-86.
33. Irisarri M, Plumas J, Bonnefoix T, Jacob MC, Roucard C, Pasquier MA, et al. Resistance to CD95-mediated apoptosis through constitutive c-FLIP expression in a non-Hodgkin's lymphoma B cell line. Leukemia 2000;14:2149-58.
34. Rafiq K, Bergtold A, Clynes R. Immune complex-mediated antigen presentation induces tumor immunity. J Clin Invest 2002;110:71-9.
35. Manca F, Fenoglio D, Li Pira G, Kunkl A, Celada F. Effect of antigen/antibody ratio on macrophage uptake, processing, and presentation to T cells of antigen complexed with polyclonal antibodies. J Exp Med 1991;173:37-48.
36. Dhodapkar KM, Krasovsky J, Williamson B, Dhodapkar MV. Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J Exp Med 2002;195:125-33.
37. Galili U, Repik PM, Anaraki F, Mozdzanowska K, Washko G, Gerhard W. Enhancement of antigen presentation of influenza virus hemagglutinin by the natural human anti-Gal antibody. Vaccine 1996;14:321-8.
38. Ossendorp F, Mengede E, Camps M, Filius R, Melief CJ. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med 1998;187:693-702.